Diurnal Group has plenty of potential upside (Analyst Interview)

Diurnal Group plc (LON:DNL) is the topic of conversation when Martin Hall, Analyst at Hardman a& Co joins DirectorsTalk. Martin explains why he has written two reports on the company recently, the significance of the PDUFA date, how important this approval is, forecasts, how Diurnal is to make money and other news to keep an eye out for.

Diurnal Group produces and distributes specialty pharmaceutical products. The Company offers drugs for congenital adrenal hyperplasia, insufficiency, hypothyroidism, and hypogonadism diseases.

Questions asked in this interview were:

Q1: You have been busy writing on Diurnal, with two reports published over the last month. Has a lot been going on at the company?

Q2: Can you explain exactly what a PDUFA date is?

Q3: How important is this approval?

Q4: Will it make a big difference to forecasts?

Q5: Whoever is right, that still sounds quite small; so how is Diurnal going to make money?

Q6: Is there more to go for with Diurnal?

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Diurnal Group: And then there were three

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an “Adrenal Franchise”.

    Hardman & Co

    Diurnal Group: Closely watching the regulators

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an “Adrenal Franchise”.

    Hardman & Co

    Diurnal Group Flow of regulatory approvals

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an “Adrenal Franchise”.

    Hardman & Co

    Diurnal Group $52.5m US deal strengthens balance sheet further

    Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group … and more to come (news flow)

    Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Plc Successful DITEST Phase I trial outcome

    Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort, are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful outcome of